India’s Patent Office Rules Against Boehringer Ingelheim Viramune Patent
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Patent Office in New Delhi on June 19 discarded a patent application for a pediatric version of German drug maker Boehringer Ingelheim's antiretroviral drug Viramune (nevirapine)
You may also be interested in...
A Closer Look: India Patent Disputes Heat Up For Big Pharma
MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions
A Closer Look: India Patent Disputes Heat Up For Big Pharma
MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions
Canada Clears Antibiotic Combo Of India’s Orchid
India's Orchid Chemicals and Pharmaceuticals got Canadian clearance to sell its combination piperacillin-tazobactam antibiotic. The Therapeutic Products Directorate allowed the combination of antibiotic injections for treating bacterial infections. Piperacilin is based on penicillin and tazobactam enhances its effectiveness. (Click here for more